News | November 28, 2025
GV20 Therapeutics hits milestone in AI-driven cancer therapy collaboration with Mitsubishi Tanabe Pharma
GV20 received an upfront payment and is eligible for additional milestone payments
GV20 received an upfront payment and is eligible for additional milestone payments
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
Renalyx will continue operating as an independent unit within the group
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
The viewer aims to help radiologists work smarter, faster, and more collaboratively, while reducing IT complexity and freeing up valuable clinical time
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
